- Built on real patient data, the clinical AI Scientist is designed to support clinical decision-making and research with AI
- The platform is designed to connect research and patient care, advancing the development of Biological Artificial Superintelligence in medicine.
Cleveland Clinic Abu Dhabi today announced a pioneering collaboration with Owkin to launch ‘Aila,’ the world’s first clinical artificial intelligence scientist. The advanced AI platform is designed to support real‑time clinical decision‑making and accelerate medical research using real patient data.
Bridging research and care, ‘Aila’ is designed to reason across complex datasets, generate actionable medical insights, and continuously learn, ‘Aila’ transforms how clinicians interact with data—enabling faster, more informed, and more precise decision‑making at the point of care.
‘Aila’ is designed to function as a clinical AI scientist, unlocking and connecting datasets. Through a secure, intuitive natural‑language interface, physicians will be able to query vast amounts of clinical data in real time and receive insights that previously required days or weeks of manual analysis. The platform is expected to transform fragmented information into a unified, queryable knowledge layer that delivers meaningful insights at the critical moment when clinical decisions are made.
“This collaboration reflects our commitment to innovation and our responsibility to actively create the future of healthcare,” said Dr. Georges‑Pascal Haber, Chief Executive Officer of Cleveland Clinic Abu Dhabi. “By responsibly harnessing advanced artificial intelligence built on real patient data, we are empowering our caregivers with powerful tools that enhance clinical judgment, advance discovery, and ultimately improve outcomes for the patients and communities we serve.”
The initial deployment of ‘Aila’ will focus on prostate cancer, integrating multiple clinical data sources including electronic health records, physician notes, pathology reports, and medical imaging. Supported by the UAE’s AI enabled infrastructure and built on Owkin’s agentic K Pro - purpose-built for biology platform, ‘Aila’ is engineered to scale across additional medical specialties and increasingly complex data modalities. Over time, the platform is designed to incorporate advanced data types such as multi‑omics and genomic data, supporting large‑scale precision medicine initiatives.
By enabling clinicians and researchers to dynamically explore retrospective data and identify complex clinical patterns, ‘Aila’ will create a powerful learning loop between care delivery and scientific discovery. This approach supports precision medicine at scale, accelerates research, and strengthens hospital performance through continuous monitoring of outcomes and quality indicators.
Dr. Haber added, “The deployment of this first‑of‑its‑kind clinical AI scientist underscores the UAE’s leadership in advancing healthcare innovation. Forward‑looking national investments and policies have created an environment where transformative technologies can be safely and responsibly implemented in real clinical settings, setting new benchmarks for healthcare systems regionally and globally.”
Through this collaboration, Cleveland Clinic Abu Dhabi continues to push the boundaries of what is possible in medicine, placing data, innovation, and patient outcomes at the heart of the next chapter in global healthcare.